CX3CL1 and systemic sclerosis: Starting from the analysis of plasma samples from the baseline collection timepoint of 30 SSc patients (Cohort 2), results showed increased levels of the chemokines CCL2 and CX3CL1 in SSc‐ILD patients as compared to SSc‐no ILD patients (Fig. 6A,B).